Harris Courtney E, Vaidya Vineeta, Lan Zhou, Klompas Michael, Rhee Chanu, Baden Lindsey R, Baker Meghan A
Division of Infectious Disease, Medical University of South Carolina, Charleston, South Carolina, USA.
Infection Control Department, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Open Forum Infect Dis. 2024 Jun 29;11(7):ofae367. doi: 10.1093/ofid/ofae367. eCollection 2024 Jul.
Among 495 patients who were immunocompromised and tested positive for SARS-CoV-2, polymerase chain reaction cycle thresholds remained <33 beyond 20 days more frequently in patients with hematologic malignancies, particularly those receiving B-cell-depleting or Bruton tyrosine kinase inhibitor therapy, as compared with those with solid organ malignancy (26% vs 5%).
在495名免疫功能低下且SARS-CoV-2检测呈阳性的患者中，与实体器官恶性肿瘤患者相比，血液系统恶性肿瘤患者，尤其是接受B细胞耗竭或布鲁顿酪氨酸激酶抑制剂治疗的患者，20天以上聚合酶链反应循环阈值保持<33的情况更为频繁（26%对5%）。
